Nathan J. Cherrington

1.8k citations

35 papers · 1.4k indexed · h-index 20

Pharmacology top 1%
- Pharmacogenetics and Drug Metabolism 10
- Drug-Induced Hepatotoxicity and Protection 5
Hepatology top 5%
Oncology top 5%
- Drug Transport and Resistance Mechanisms 17
Epidemiology top 5%
- Liver Disease Diagnosis and Treatment 19
Biochemistry top 5%
Molecular Biology
- Genomics, phytochemicals, and oxidative stress 4
Cell Biology
- Endoplasmic Reticulum Stress and Disease 3
Endocrinology, Diabetes and Metabolism
- Diet, Metabolism, and Disease 3
Pediatrics, Perinatology and Child Health
- Pharmacological Effects and Toxicity Studies 3

Co-authors: Craig D. Fisher Andrew J. Lickteig Lisa M. Augustine Matthew D. Merrell Curtis D. Klaassen Angela L. Slitt Jonathan P. Jackson Dylan P. Hartley
Cited by: Pharmacology Hepatology Oncology
Journals: Journal of Biological Chemistry (1 paper)Gastroenterology (1 paper)The FASEB Journal (2 papers)
Partner nations: United States Japan Canada

In The Last Decade

Nathan J. Cherrington

34 papers receiving 1.4k citations

Peers

Countries citing papers authored by Nathan J. Cherrington

Since Specialization

Citations

This map shows the geographic impact of Nathan J. Cherrington's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nathan J. Cherrington with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nathan J. Cherrington more than expected).

Fields of papers citing papers by Nathan J. Cherrington

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nathan J. Cherrington. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nathan J. Cherrington. The network helps show where Nathan J. Cherrington may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Nathan J. Cherrington, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Nathan J. Cherrington Line = papers co-authored together Nathan J. Cherrington links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nonalcoholic steatohepatitis increases plasma retention of sorafenib-glucuronide in a mouse model by altering hepatocyte hopping Acta Pharmaceutica Sinica B ·Erica Toth,Hui Li,Kayla L. Frost,Paxton A. Sample,Joseph L. Jilek,Siennah R. Greenfield,Dahea You,Danielle Kozlosky,Michael Goedken,Mary F. Paine,Lauren M. Aleksunes,Nathan J. Cherrington	2024	0
2	Restoration of the ER stress response protein TDAG51 in hepatocytes mitigates NAFLD in mice Journal of Biological Chemistry ·Tamana Yousof,Celeste Bouchard,Mihnea Alb,Edward G. Lynn,Šárka Lhoták,Hua Jiang,Melissa E. MacDonald,Hui Li,Jae Hyun Byun,Yumna Makda,Maria Athanasopoulos,Kenneth N. Maclean,Nathan J. Cherrington,Asghar Naqvi,Suleiman A. Igdoura,Joan C. Krepinsky,Gregory R. Steinberg,Richard C. Austin	2024	2
3	Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination Drug Metabolism and Disposition ·Kayla L. Frost,Joseph L. Jilek,Shripad Sinari,Robert Klein,Dean Billheimer,Stephen H. Wright,Nathan J. Cherrington	2022	9
4	Attenuated Ochratoxin A Transporter Expression in a Mouse Model of Nonalcoholic Steatohepatitis Protects against Proximal Convoluted Tubule Toxicity Drug Metabolism and Disposition ·Joseph L. Jilek,Kayla L. Frost,Solène Marie,Cassandra M. Myers,Michael Goedken,Stephen H. Wright,Nathan J. Cherrington	2021	5
5	Altered cisplatin pharmacokinetics during nonalcoholic steatohepatitis contributes to reduced nephrotoxicity Acta Pharmaceutica Sinica B ·Joseph L. Jilek,Kayla L. Frost,Kevyn A. Jacobus,Wenxi He,Erica Toth,Michael Goedken,Nathan J. Cherrington	2021	10
6	Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH Toxicological Sciences ·Hui Li,Erica Toth,Nathan J. Cherrington	2017	29
7	Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21st International Symposium on Microsomes and Drug Oxidations (MDO) Acta Pharmaceutica Sinica B ·Ai‐Ming Yu,Magnus Ingelman‐Sundberg,Nathan J. Cherrington,Lauren M. Aleksunes,Ulrich M. Zanger,Wen Xie,Hyunyoung Jeong,Edward T. Morgan,Peter J. Turnbaugh,Curtis D. Klaassen,Aadra P. Bhatt,Matthew R. Redinbo,Pengying Hao,David J. Waxman,Li Wang,Xiao-bo Zhong	2017	22
8	Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression Drug Metabolism and Disposition ·Ajay C. Donepudi,Qiaoyun Cheng,Zhijian Lu,Nathan J. Cherrington,Angela L. Slitt	2016	11
9	Organic and inorganic transporters of the testis: A review PubMed ·David Klein,Nathan J. Cherrington	2014	12
10	Downregulation of Sulfotransferase Expression and Activity in Diseased Human Livers Drug Metabolism and Disposition ·Emine Yalçın,Vijay R. More,Karissa L. Neira,Zhenqiang Lu,Nathan J. Cherrington,Angela L. Slitt,Robert J. King	2013	44
11	Alcohol Cirrhosis Alters Nuclear Receptor and Drug Transporter Expression in Human Liver Drug Metabolism and Disposition ·Vijay R. More,Qiuqiong Cheng,Ajay C. Donepudi,David B. Buckley,Zhenqiang Lu,Nathan J. Cherrington,Angela L. Slitt	2013	36
12	Drug metabolism alterations in nonalcoholic fatty liver disease Drug Metabolism Reviews ·Matthew D. Merrell,Nathan J. Cherrington	2011	131
13	S1840 Acetaminophen Disposition: A Novel Marker for Patients With Nonalcoholic Fatty Liver Disease Gastroenterology ·Hassan H. A‐Kader,Matthew D. Merrell,Robert V. Erickson,Nathan J. Cherrington	2010	1
14	Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats European Journal of Pharmacology ·Craig D. Fisher,Andrew J. Lickteig,Lisa M. Augustine,Ronald P.J. Oude Elferink,David G. Besselsen,Robert P. Erickson,Nathan J. Cherrington	2009	91
15	Hepatic Cytochrome P450 Enzyme Alterations in Humans with Progressive Stages of Nonalcoholic Fatty Liver Disease Drug Metabolism and Disposition ·Craig D. Fisher,Andrew J. Lickteig,Lisa M. Augustine,James Ranger‐Moore,Jonathan P. Jackson,Stephen Ferguson,Nathan J. Cherrington	2009	268
16	Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis Archives of Toxicology ·Craig D. Fisher,Jonathan P. Jackson,Andrew J. Lickteig,Lisa M. Augustine,Nathan J. Cherrington	2008	45
17	Efflux Transporter Expression and Acetaminophen Metabolite Excretion Are Altered in Rodent Models of Nonalcoholic Fatty Liver Disease Drug Metabolism and Disposition ·Andrew J. Lickteig,Craig D. Fisher,Lisa M. Augustine,Lauren M. Aleksunes,David G. Besselsen,Angela L. Slitt,José E. Manautou,Nathan J. Cherrington	2007	83
18	Endocrine Regulation of Rat Organic Anion Transporters Drug Metabolism and Disposition ·Susan Buist,Nathan J. Cherrington,Curtis D. Klaassen	2003	56
19	Tissue Distribution and Renal Developmental Changes in Rat Organic Cation Transporter mRNA levels Drug Metabolism and Disposition ·Angela L. Slitt,Nathan J. Cherrington,Dylan P. Hartley,Tyra M. Leazer,Curtis D. Klaassen	2002	128
20	Molecular Cloning, Sequencing, and Expression inEscherichia coliof Mouse Flavin-Containing Monooxygenase 3 (FMO3): Comparison with the Human Isoform Archives of Biochemistry and Biophysics ·J.Greg Falls,Nathan J. Cherrington,Kieran M. Clements,Richard M. Philpot,Patricia E. Levi,Randy L. Rose,Ernest Hodgson	1997	32

About Nathan J. Cherrington

Nathan J. Cherrington is a scholar working on Pharmacology, Hepatology and Oncology, having authored 35 papers that have together received 1.4k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (19 papers), Drug Transport and Resistance Mechanisms (17 papers), Pharmacogenetics and Drug Metabolism (10 papers), Drug-Induced Hepatotoxicity and Protection (5 papers), Genomics, phytochemicals, and oxidative stress (4 papers), Endoplasmic Reticulum Stress and Disease (3 papers), Diet, Metabolism, and Disease (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). The work is most often cited by research in Pharmacology (362 citations), Hepatology (197 citations) and Oncology (504 citations). Nathan J. Cherrington has collaborated with scholars based in United States, Japan and Canada. Frequent co-authors include Craig D. Fisher, Andrew J. Lickteig, Lisa M. Augustine, Matthew D. Merrell, Curtis D. Klaassen, Angela L. Slitt, Jonathan P. Jackson, Dylan P. Hartley, Stephen Ferguson and James Ranger‐Moore. Their work appears in journals such as Journal of Biological Chemistry, Gastroenterology and The FASEB Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact